loading...| Preferred Name |
Samuraciclib |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155652 |
| CAS_Registry |
1805833-75-3 |
| code |
C155652 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
| Contributing_Source |
GDC FDA |
| DEFINITION |
An orally available, selective inhibitor of cyclin-dependent kinase 7 (CDK7) with potential antineoplastic activity. Upon oral administration, samuraciclib selectively and competitively binds to the CDK7 ATP binding site, thereby inhibiting CDK7-mediated signaling. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc through the phosphorylation of RNA polymerase II. Inhibition of CDK7 may inhibit tumor cell proliferation in certain cancers that are dependent on CDK7-mediated transcriptional regulation and signaling. |
| FDA_UNII_Code |
46D4HS9ODA |
| FULL_SYN |
CDK7 Inhibitor CT7001 Samuraciclib SAMURACICLIB CT7001 CT 7001 CT-7001 |
| Is_Value_For_GDC_Property | |
| label |
Samuraciclib |
| Maps_To |
CDK7 Inhibitor CT7001 Samuraciclib |
| NCI_Drug_Dictionary_ID |
794642 |
| NCI_META_CUI |
CL556268 |
| PDQ_Closed_Trial_Search_ID |
794642 |
| PDQ_Open_Trial_Search_ID |
794642 |
| Preferred_Name |
Samuraciclib |
| prefixIRI |
Thesaurus:C155652 |
| prefLabel |
Samuraciclib |
| Semantic_Type |
Pharmacologic Substance |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| There are currently no mappings for this class. | |||